Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.
The Scientist
Most Recent
The Justices have decided that isolated sequences of human DNA are not eligible for patent protection, but rules that artificial sequences can be patented.
As reproductive tissues age, DNA repair mechanisms become less efficient, causing genomic damage to accumulate.
The Supreme Court agrees to hear a case deciding if two cancer genes should continue to be protected by patent.
Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.
A public interest legal group has renewed the fight against DNA patenting.
Mutations known to increase the risk of developing ovarian and breast cancer may also make carriers susceptible to heart failure.
The age at which BRCA carriers are diagnosed with breast cancer may depend on which parent contributed the mutation.
The case challenging the right of a healthcare company to patent cancer genes may make it all the way to the US Supreme Court.
A snapshot of the most highly ranked articles in molecular biology, from Faculty of 1000
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Advertisement
Current Issue
